摘要:
Disclosed is a method of tailoring infant formulas to individual nutrition needs prior to use. The method comprises (A) determining the desired volume and optimal caloric density of a formula to be fed to a preterm or low birth weight infant; (B) obtaining a plurality of base infant formulas, all in liquid form, comprising fat, protein, carbohydrate, vitamins, and minerals, each of which has an osmolality of from about 200 to about 360 mOsm/kg water and a different caloric density within a range of from about 609 to about 1082 kcal/L; (C) selecting two of the base liquid formulas having a caloric density value above and below the optimal caloric density, (D) calculating the volume of each selected base formula needed to produce the desired volume of an infant formula blend having the optimal caloric density; (E) combining the calculated volumes to produce a an isotonic blend having the desired feeding volume and optimal caloric density. The formula is then fed to the preterm or low birth weight infant. Also disclosed is a hypercaloric infant formula suitable for use in the disclosed method, and infant formula kits comprising the plurality of base formulas and a device (e.g. calculator, computer program, chart with precalculated blend volumes) for calculating blend volumes.
摘要:
Disclosed are concentrated, liquid, human milk fortifier compositions comprising from about 15% to about 45% by weight of protein, on a dry weight basis, and having a caloric density of from about 1.25 kcauml to about 6.0 kcau/ml, wherein the liquid human milk fortifier composition is added to human milk in a volume-volume ratio of from about 1:3 to about 1:9. These composition include embodiments comprising carbohydrate and fat, that are formulated with improved stability by selecting any one of the following variations: 1) certain whey-casein protein blends, 2) water insoluble calcium-containing materials, 3) protein hydrolysates, and 4) aseptically packaged concentrates. The liquid concentrates are especially useful for providing nutrition to preterm infants in neonatal intensive care units or similar other institutional setting, and to minimize the risk of introducing microbial contaminants such as Enterobacter sakazakii to infant feedings during preparation in such institutional settings.
摘要:
The present invention provides a food product comprising: a formed reduced glycemic response cereal component; and a non-sticky reduced glycemic response sweetener coating over the formed cereal component, the sweetener coating comprising: a first sticky layer comprising at least about 30% fructose (of the total sweetener coating); a second less sticky layer having a DE value of about 60 or less and comprising up to about 17% fructose and at least about 1% non-fructose carbohydrates (of the total sweetener coating); and third layer comprising crystalline fructose. The present invention also provides a process for forming the sweetener coating over the formed cereal component comprising the following steps: (a) providing a formed cereal component having thereon a first sticky layer comprising fructose; (b) forming over the first sticky layer a less stick second layer comprising non-fructose carbohydrates and optionally fructose; and (c) applying crystalline fructose over the second layer.
摘要:
Methods for sequentially removing isoflavones and phytates from an active surface by utilizing an aqueous medium for isoflavone removal and an aqueous medium for phytate removal. The aqueous medium for isoflavone removal contains at least one alcohol and at least one acid. The aqueous medium for phytate removal is either a relatively stronger acidic solution, a basic solution, or with some active surfaces may be an aqueous solution of pH 2-7, which is essentially free of alcohol and organic solvents. The use of the methods disclosed allows sequential isolation of isoflavones and phytates, compounds which may then be utilized in various foods for human consumption.
摘要:
Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.
摘要:
Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 μg selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.